Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Greenwich LifeSciences (GLSI) Net Cash Flow (2019 - 2025)

Greenwich LifeSciences filings provide 7 years of Net Cash Flow readings, the most recent being $681877.0 for Q3 2025.

  • Quarterly Net Cash Flow rose 148.62% to $681877.0 in Q3 2025 from the year-ago period, while the trailing twelve-month figure was -$2.0 million through Sep 2025, up 39.32% year-over-year, with the annual reading at -$2.9 million for FY2024, 55.28% up from the prior year.
  • Net Cash Flow hit $681877.0 in Q3 2025 for Greenwich LifeSciences, up from $375142.0 in the prior quarter.
  • Across five years, Net Cash Flow topped out at $1.7 million in Q1 2021 and bottomed at -$7.5 million in Q1 2022.
  • Average Net Cash Flow over 5 years is -$1.3 million, with a median of -$1.5 million recorded in 2024.
  • The largest annual shift saw Net Cash Flow crashed 527.68% in 2022 before it surged 277.76% in 2024.
  • Greenwich LifeSciences' Net Cash Flow stood at -$1.7 million in 2021, then fell by 27.52% to -$2.2 million in 2022, then increased by 0.73% to -$2.2 million in 2023, then grew by 19.67% to -$1.7 million in 2024, then skyrocketed by 139.41% to $681877.0 in 2025.
  • Per Business Quant, the three most recent readings for GLSI's Net Cash Flow are $681877.0 (Q3 2025), $375142.0 (Q2 2025), and -$1.3 million (Q1 2025).